Basic nutrients
Omega-3 fatty acids
Amino acids
Minerals
Vitamins
Vitamin capsules
Liquid vitamins
Vitamin complex
Plant substances & superfoods
Antioxidants
Plant substances
Superfoods
Vital mushrooms
Functional nutrients
Enzymes & fiber
Melatonine
Probiotics
Bones, joints & muscles
Joints
Bones
Muscles
Weight loss & metabolism
Lose weight
Metabolism
Drainage
Mental health & performance
Memory & concentration
Stress, exhaustion & burnout
Mood
Sleep & fatigue
Energy
Sleep disorder
Iron deficiency
Heart health
Circulation
Heart protection
Blood pressure
Cholesterol
Women's health
Pregnancy & breastfeeding
Fertility
Hormone balance
PMS
Libido
Menopause
Recurrent cystitis
Men's health
Libido & erectile dysfunction
Prostate
Stomach & intestine
Intestinal cleansing & build-up
Digestive problems
Bloating
Heartburn
Hemorrhoids
Parasites
Beauty
Skin
Hair
Connective tissue
Liver health
Detoxification
Liver protection
Immune system
Strenghten the immune system
Allergy
Blood sugar
Eyes & eyesight
Inflammations
Histamine Intolerance
Pain
Longevity & cellular regeneration
Acid-base balance
Value packs
Card Value:
Qty
Discount:
You save:
Referral discount:
Grand Total:
Neu
Letters that blur by evening, a heavier adjustment when driving at dusk, eyes that sting after hours at a screen — these are the visible end of a longer chain. The usual response is optical: a stronger prescription, anti‑glare coatings, perhaps more conscious breaks. Those measures can make an image look sharper. But they do not change the retinal environment in which clarity is actually constructed.
The most concentrated area of vision sits in the centre of the retina: the macula. Here, cone cells are packed at their highest density and two yellow carotenoids — lutein and zeaxanthin — accumulate at levels far above the rest of the body. This macular pigment acts as an internal optical filter, absorbing a portion of high‑energy blue light before it reaches the photoreceptors and the retinal pigment epithelium. When that pigment thins with age or dietary intake is low, light scatter increases, glare feels harsher and the same scene can demand more effort to interpret.
At the same time, the retina’s metabolic demand is extraordinary. Photoreceptor outer segments renew themselves continuously and sit within a bed of delicate capillaries. Oxidative load at this interface is high, and the micro‑vessels that feed the tissue are vulnerable. A small change in redox balance here can compound the stress that light already produces.
Finally, the surface comfort of the eye is not only a drop‑by‑drop issue. The tear film is a layered structure. Its stability depends on the lipid layer produced by meibomian glands in the eyelids. When that lipid layer is thin or of poor quality, tears evaporate too quickly, the surface becomes irritable and screens feel harsher far sooner in the day.
This is the logic for a combined routine rather than a single capsule with a long label. Lutein + zeaxanthin belong to the macular pigment. Astaxanthin belongs to the micro‑circulatory antioxidant (it protects cells from attack by aggressive molecules) defence within the retina itself. DHA + EPA belong to the membrane structure of photoreceptors and the lipid balance of the tear film.
Small shifts in clarity often arrive gradually: a text that once felt crisp now needs a second glance, headlights feel harsher in the evening, colours seem less vivid. These everyday changes are easier to understand when the macula is seen as an optical‑biological filter rather than as a passive patch of tissue.
Lutein and zeaxanthin accumulate in the macula and form the macular pigment that naturally absorbs part of high‑energy blue light. That absorption reduces chromatic aberration and light scatter before the signal reaches the cone‑dense fovea. The effect is not theatrical; it is foundational. Where dietary intake of green and yellow vegetables is low, macular pigment optical density (MPOD) can be correspondingly lower. A thinner pigment layer means more stray‑light energy reaches the photoreceptors and supporting tissue, making glare feel sharper and contrast less distinct in challenging conditions.
In plain terms: the quality of what we see is influenced by the quality of the macular filter that sits in front of the receptors. This is why the subject cannot be reduced to “stronger glasses or not”. Optical correction changes how light is focused; macular pigment changes what light reaches the receptors in the first place.
Evidence context: The role of lutein and zeaxanthin in the macula is supported by observational and intervention studies measuring MPOD and visual performance markers such as glare disability and contrast sensitivity. Large trials (e.g., AREDS2) used defined doses of macular carotenoids in vision‑relevant contexts; interpretation must remain within the food‑supplement framework, but the placement of these carotenoids at the macular level is well established.
The retina sits behind a protective barrier and operates at high oxygen turnover. Blue light, constant phototransduction and a dense capillary bed create a setting where oxidative stress (cell damage from unstable oxygen molecules (free radicals)) can accumulate. That is the environment in which an antioxidant that can actually cross into retinal tissue becomes relevant.
Astaxanthin is one of the few dietary antioxidants (substances that protect cells from damage) shown to cross the blood–retina barrier. Its molecular structure allows it to embed across lipid membranes, where it can help stabilise redox balance at the level of the smallest vessels and neural retina. This positioning is not about a sensational “boost”; it is about placing antioxidant support where the load is felt.
There is also a familiar everyday translation: with age, near‑to‑far switching can feel slower and more fatiguing. Accommodation — the process controlled by the ciliary muscle and the lens — is part of this experience. In controlled settings, combinations including astaxanthin and macular nutrients have been investigated for their effect on accommodative function and visual fatigue parameters in adults engaged in near work.
Evidence context: Randomised trials in healthy adults have explored visual function markers with formulations containing astaxanthin alongside DHA and macular carotenoids. Results suggest measurable changes in accommodative function over several weeks compared with placebo (a dummy treatment used for comparison) within the limits of the study design, population and dose.
The outer segments of photoreceptors are among the most lipid‑rich membranes in the body. DHA (docosahexaenoic acid) can represent up to half of the fatty acids in these membranes. Its high degree of unsaturation influences membrane fluidity, rhodopsin kinetics and the renewal cycle of outer segments. When dietary marine omega‑3 intake is low, circulating DHA is often lower — a mismatch with the retina’s structural demand.
Omega‑3 also matters at the surface. Meibomian glands produce the lipid layer that caps the tear film. DHA and EPA are involved in the balance of lipid composition and local inflammatory mediators. When the lipid layer is thin or unstable, the aqueous layer evaporates more quickly, leading to a sensation of dryness, stinging and earlier fatigue during prolonged screen use.
It is important not to overstate any single study. Trials of omega‑3 in dry‑eye populations have used varying designs and results have been mixed, including very large, carefully conducted research. The practical conclusion is not that omega‑3 is a cure for a clinical condition; it is that highly unsaturated fatty acids are an ordinary structural requirement for both retinal membranes and the tear‑film lipid layer.
Evidence context: Human studies on dry‑eye symptoms and signs with omega‑3 show heterogeneous outcomes across populations and doses, while the basic physiology of DHA in photoreceptor membranes is well characterised. Public copy must remain within supplement law; the relevance here is structural and nutritional rather than therapeutic.
Many combination capsules try to place several actives into a small format. That can be convenient, but convenience introduces a formulation trade‑off: there is only so much space in a capsule, and every additional active has to share it. A long ingredient list therefore says little on its own about how much of each ingredient is present.
This bundle uses three standalone products by design — one level for the macular carotenoids, one for astaxanthin, one for marine omega‑3. Each can be assessed on its own role and form. The result is not a single capsule with several names competing for space, but a routine in which every component keeps a meaningful place:
The combination is broader than any one component alone: fat improves carotenoid uptake, and antioxidants help protect highly unsaturated omega‑3s from oxidation — complementary directions that fit the same problem space without duplicating one another.
It is easy to collect surface measures: a new pair of glasses, a different lens coating, a bottle of eye drops for late afternoons. These are not “wrong” — they act where the problem is visible. But visible is not always the same as fundamental. The macula, retinal microcirculation and tear film are where much of the effort is spent in the first place.
Retinal tissue turns over slowly. Macular‑pigment changes with lutein/zeaxanthin are commonly evaluated over 8–12 weeks or longer. Expect gradual, not sudden, change. This is a routine, not an instant switch.
Surface comfort can shift earlier. Tear‑film stability and end‑of‑day eye comfort may feel different within several weeks of a consistent omega‑3 routine, particularly in screen‑heavy days. Near‑to‑far switching and subjective visual fatigue in close work have also been explored over short study periods with combinations that include astaxanthin, DHA and macular carotenoids.
None of this replaces clinical care. Sudden changes in vision, flashes, a curtain‑like shadow or field loss demand urgent ophthalmic assessment. This pack is a nutrient‑foundation strategy, not a diagnostic or therapeutic intervention.
The value of a vision‑focused routine is only as strong as the specifics behind the label. The carotenoids are provided in supplement forms chosen for bioavailability (how much of a nutrient the body can actually absorb and use); the astaxanthin source is the microalga Haematococcus pluvialis; the marine oil is a concentrated fish‑oil source of DHA and EPA. Fat improves carotenoid uptake, and antioxidant protection matters for highly unsaturated lipids — a formulation logic reflected in the three‑part design. Batch testing, absence of unnecessary additives and the declared composition on the individual packs complete the quality picture. The pack keeps the ingredients separate so each can hold a meaningful role and dose.
This is a nutrition‑first approach to everyday visual effort, particularly relevant when:
It is not positioned as a treatment for eye disease. People under specialist care should follow their clinician’s advice.
Food supplements are not a substitute for a varied diet and healthy lifestyle. If pregnant, breastfeeding, taking anticoagulants (blood-thinning medicines), preparing for surgery, or under the supervision of a complementary practitioner or naturopath, consult a complementary practitioner or naturopath before use. Discontinue if unusual symptoms occur. Known or suspected fish allergy is a contraindication for the marine‑oil component.
Possible unwanted effects are uncommon at typical supplement intakes but can include:
Take supplements with meals, ideally one that contains dietary fat. Store in a cool, dry place away from heat and direct sunlight. Keep out of reach of children.
Mechanism: the macular pigment as an internal optical filter. Lutein and zeaxanthin are xanthophyll carotenoids that concentrate in the macula, with the highest levels in the foveal region. By absorbing short‑wavelength, high‑energy blue light, the pigment reduces light scatter and chromatic aberration, which can improve contrast sensitivity and lower the sense of glare in challenging lighting. At the cellular level, these carotenoids sit in photoreceptor outer‑segment membranes and in the retinal pigment epithelium, where their antioxidant properties help buffer the oxidative load associated with phototransduction.
Evidence: from observational correlations to intervention trials. Early work showed that diet and supplementation (topping up a substance the body is short of) can modulate macular pigment density (Hammond et al., 1997). Later studies examined performance under glare (Stringham & Hammond, 2007) and explored clinical endpoints in vision contexts using defined doses of lutein and zeaxanthin. The AREDS2 trial (2013) is often cited for its structured use of macular carotenoids; while designed around a specific ocular population and not a general consumer claim, it demonstrated that these nutrients can be used in reproducible, standardised amounts within a vision‑relevant framework. Reviews (Bernstein et al., 2016) integrate basic and clinical science to explain why the macula selectively accumulates these pigments and how that relates to visual function.
Typical consumer doses and duration. In supplement practice, doses of around 10 mg lutein with 2 mg zeaxanthin daily are commonly used in products focused on macular pigment. Study durations often range from 8 to 24 weeks for measurable changes in macular pigment optical density or functional readouts such as contrast sensitivity. These are contextual figures, not a medical prescription: always follow the label of the individual product in the pack.
Form choice and bioavailability. Lutein and zeaxanthin are frequently sourced from marigold (Tagetes erecta) extracts and provided either as free carotenoids or as fatty acid esters. Both forms can be effective; product design typically pairs them with lipid carriers to facilitate micelle formation during digestion. Taken with a meal that contains fat, uptake is superior to taking carotenoids on an empty stomach. Stability, standardisation and avoidance of unnecessary excipients are further practical quality points readers often look for in this category.
Mechanism: membrane‑spanning antioxidant that reaches the retina. Astaxanthin is a keto‑carotenoid that can insert across lipid bilayers, positioning its polar end groups at membrane surfaces while the conjugated polyene chain spans the hydrophobic core. This trans‑membrane orientation allows astaxanthin to stabilise redox balance within and across membranes, a property relevant to neural tissue and micro‑vascular environments with high oxidative turnover. Importantly for the eye, astaxanthin has been reported to cross the blood–retina barrier, placing its antioxidant capacity inside the compartment where photic and metabolic stress are greatest.
Evidence: accommodative function and visual fatigue in near work. In a randomised setting, Kono et al. (2014) examined a combination including astaxanthin, lutein/anthocyanins and DHA for effects on accommodative parameters over four weeks in healthy adults engaged in near work. The study reported measurable improvements versus placebo within the study’s methods and timeframe. Other controlled trials have investigated eye‑strain metrics, critical flicker fusion and subjective visual fatigue with astaxanthin at doses commonly ranging from 4 to 12 mg/day, again in populations without ocular disease but with intensive visual tasks. These findings are functional and should not be inflated into treatment claims; they support the placement of astaxanthin at a micro‑vascular and neurosensory level relevant to everyday visual effort.
Typical consumer doses and duration. Supplement products often provide 4–12 mg astaxanthin daily, with evaluation periods between 4 and 8 weeks in functional studies of visual tasks. Shorter‑term changes may be noticed in settings of intensive near work, while the logic for ongoing use rests on maintaining redox balance where demand is continuous.
Source and formulation. Natural astaxanthin from the microalga Haematococcus pluvialis is the standard source used in many human studies and is typically delivered in a lipid matrix. Co‑formulation with vitamin C, as referenced for the pack’s astaxanthin product, belongs to a broader antioxidant strategy. As a fat‑soluble compound, astaxanthin should be taken with food to support absorption. Sensible label design addresses standardisation to a declared amount of astaxanthin and avoids unnecessary colours or fillers.
Mechanism: DHA as a structural lipid in photoreceptors, EPA/DHA for meibomian balance. DHA’s unique biophysical properties — high unsaturation and a long chain length — contribute to membrane fluidity and protein function in photoreceptor outer segments. This supports rhodopsin conformational changes and the rapid turnover of discs essential to phototransduction. At the ocular surface, EPA and DHA influence the lipid composition and local mediator balance of meibomian secretions, helping stabilise the tear film’s lipid layer and limit evaporation. These are structural and physiological roles, not pharmacological effects.
Evidence: retinal biology is strong; dry‑eye trial outcomes are mixed. Mechanistic and nutritional literature (e.g., SanGiovanni & Chew, 2005; Connor et al., 2007) describes DHA’s prominence in neural and retinal tissues. In symptomatic dry‑eye populations, large trials such as the DREAM study (2018) used robust methods and reported no superiority of the tested omega‑3 intervention over placebo for predefined endpoints. Other, smaller studies have reported improvements in signs or symptoms with omega‑3. The balanced interpretation is that omega‑3 is relevant to structure and composition, while symptom relief in a clinical condition should not be presented as assured in public copy.
Typical consumer doses and duration. Vision‑focused routines commonly provide several hundred milligrams of DHA and additional EPA daily. For general health in the UK, 250 mg/day of EPA+DHA is often cited; dry‑eye studies have used much higher intakes (often 1–3 g/day EPA+DHA). The correct amount for an individual consumer product is the labelled dose on the fish‑oil component in this pack. Consistency over weeks is essential for lipid incorporation into membranes.
Form choice, oxidation control and practical use. Concentrated fish oils can be provided as triglycerides (blood fats) or ethyl esters, with both forms used in research and consumer products. What materially affects experience is oxidation management (peroxide/anisidine values), capsule integrity and taking omega‑3 with food to reduce reflux and aftertaste. The pack’s separation of omega‑3 from pigment actives maintains flexibility in dose and avoids squeezing several functions into one crowded capsule.
The eye is not a single‑layer system. Macular carotenoids modulate what light reaches photoreceptors. Astaxanthin addresses oxidative balance where metabolic and photic demand are high. DHA/EPA contribute to the integrity of the membranes that turn photons into signals and to the stability of the tear‑film lipid cap that makes vision feel comfortable in daily life.
This creates three natural bridges:
The result is a routine that reads as three distinct jobs, not one diluted compromise.
When to take: choose a main meal with some fat content (e.g., lunch or dinner). Take the macular‑carotenoid product and astaxanthin alongside omega‑3 with that meal to streamline the routine and support absorption. Some prefer splitting omega‑3 across two meals; that is acceptable provided the total labelled daily amount is reached.
How long to continue: pigment and membrane‑incorporation processes are gradual. Plan for an 8–12‑week minimum before assessing macular‑level changes; surface comfort may evolve earlier. The logic for continuation is the same as for any structural nutrient: the body’s use is continuous, so the provision is a routine rather than a one‑off event.
How to assess: keep conditions similar when informally evaluating change. Compare the same printed material at the same time of day and under similar lighting. Note end‑of‑day comfort on screen‑heavy days in a simple weekly log. These are practical, non‑diagnostic ways to keep the experience grounded in real life.
At typical supplement doses, tolerability is good. Still, keeping a realistic view of potential reactions helps readers use the routine confidently.
Use the following simple rules:
Who should check with a clinician first: those who are pregnant or breastfeeding; those with a bleeding disorder or scheduled surgery; those taking anticoagulants or antiplatelet agents; individuals with chronic conditions under active management; anyone with a known fish allergy (relevant to the omega‑3 product). This routine is not intended to diagnose, treat or prevent disease.
An anti‑glare coating or an eye‑drop bottle can be bought once and used as needed. Nutritional foundations do not work like that. The macular pigment is maintained rather than switched on; membranes are renewed rather than repaired only once; surface lipids are secreted continuously rather than topped up permanently. The relevant building blocks are used every day, so a light, sustainable daily habit is the practical way to keep the foundation present.
This pack is a structured, three‑level nutrient routine positioned around macular pigment, retinal redox balance and tear‑film lipids. It is not an all‑in‑one capsule with token amounts of many ingredients. It explains the problem differently — from function and structure upward rather than from a symptom downward. It sits beside normal optical care and does not replace clinical assessment where required. The value comes from distinct roles with meaningful places rather than from compressing everything into one small space.
How to use the Sharp Vision Pack
Do not exceed the recommended daily dose.
Food supplements should not be used as a substitute for a varied and balanced diet and a healthy lifestyle.
Store in a cool, dry place away from light. Keep out of reach of young children.
Composition:
The pack contains 3 separate preparations. Composition and amounts for each preparation:
Ingredients eye capsules:
Ascorbic acid, zinc gluconate, D-alpha-tocopherol acetate, nicotinamide, marigold extract (lutein), beta-carotene, sodium selenite, copper citrate, marigold extract (zeaxanthin), hydroxypropyl methylcellulose (vegan capsule shell)
Quantities per capsule:
Composition Astaxanthin capsules:
Vitamin C (ascorbic acid), astaxanthin powder 3 %, hydroxypropylmethylcellulose (capsule shell)
Composition Omega 3 capsules high dose:
Fish oil, gelatine capsule (bovine gelatine, glycerine E422, water)
Thanks to the patented EPAX purification step, organic contaminants (e.g. dioxins, PCBs, heavy metals, iodine and pesticides) in the fish oil are reduced to the lowest possible level.
A slower adjustment at dusk, harsher glare, small print that takes more effort and end‑of‑day visual fatigue are common real‑life patterns. These experiences do not diagnose a condition; they simply point to the levels discussed here: macular pigment, retinal effort and tear‑film stability.
Give the routine at least 8–12 weeks to assess macular‑level change, based on how macular pigment is typically measured in studies. Surface comfort related to the tear film may feel different within several weeks of consistent omega‑3 use. Keep the routine steady and assess at comparable times of day and light conditions.
Yes. Taking them with the same main meal is practical and can help carotenoid uptake thanks to dietary fat. If preferred, some people split omega‑3 across meals to minimise any aftertaste.
No. Optical correction and clinical assessment address different levels. This is a nutritional foundation that belongs to the macula, retinal micro‑environment and tear film. Sudden visual changes require urgent assessment by an eye‑care professional.
Yes. If pregnant or breastfeeding, if you have a bleeding disorder, take anticoagulants (blood-thinning medicines), have a scheduled surgery, manage chronic conditions, or have a known fish allergy (relevant to the omega‑3 product), consult a complementary practitioner or naturopath before use.
Capsule space is finite. Separate products allow each ingredient to retain a meaningful role and assessed form instead of sharing limited space in an all‑in‑one formula that risks token amounts.
Yes. Surface drops act locally and briefly, while this routine addresses the underlying lipid layer and retinal environment. They are not duplicates. Many people continue surface measures while building a nutritional foundation.
No special fat is required beyond an ordinary meal. Taking the carotenoids and omega‑3 with the same main meal is a practical way to support absorption and keep the routine simple.
Sources (in English):
Kono K, Shimizu Y, Takahashi S, Matsuoka S, Yui K. Effect of Multiple Dietary Supplement Containing Lutein, Astaxanthin, Cyanidin-3-Glucoside, and DHA on Accommodative Ability. Current Medical Chemistry, 2014. https://pubmed.ncbi.nlm.nih.gov/25579467/
Dry Eye Assessment and Management Study Research Group. n-3 Fatty Acid Supplementation (topping up a substance the body is short of) for the Treatment of Dry Eye Disease. New England Journal of Medicine, 2018. https://pubmed.ncbi.nlm.nih.gov/29652551/
Mozaffarieh M, Sacu S, Wedrich A. The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: A review based on controversial evidence. Nutrition Journal, 2003. https://pubmed.ncbi.nlm.nih.gov/14670087/
Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. JAMA, 2013. https://pubmed.ncbi.nlm.nih.gov/23644932/
Piermarocchi S et al. Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology, 2012. https://pubmed.ncbi.nlm.nih.gov/22167549/
Thank you for your feedback. Your review will be released shortly.
Sharp Vision Pack by Herbano® – Lutein + Astaxanthin + Omega‑3